Brainreader
Brainreader is a Danish medtech company (founded 2011) that sells Neuroreader, an FDA-cleared AI software that quantifies 83 brain regions from routine MRI scans in under 10 minutes to support diagnosis and monitoring of neurodegenerative diseases for hospitals, imaging centers, and neurology/radiology practices.
- Company typePrivate
- Founded2011
- HeadquartersAalborg, Denmark
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Brainreader does
Brainreader A/S is a Danish medtech company founded in 2011 by Jamila Ahdidan, PhD, that develops Neuroreader, an FDA-cleared and CE-marked AI-enabled software for automated brain volumetric analysis from routine MRI scans. The software segments and quantifies 83 brain regions in under 10 minutes, compares measured volumes against an FDA-cleared normative database of healthy brain tissue, and outputs reports containing volumes, percentiles, and Z-scores to support diagnosis and longitudinal monitoring of neurodegenerative conditions including Alzheimer's disease, mild cognitive impairment, traumatic brain injury, and frontotemporal dementia. Workflow integration is achieved via PACS mediation server or web upload with no hardware costs, enabling adoption as a routine MRI add-on.
The company sells to hospitals and health systems, imaging centers, neurology and radiology practices, and academic/research institutions via a pay-per-use model (approximately $70 per scan, reimbursable under CPT code 76377) and subscription licensing. Its core go-to-market combines direct enterprise sales — recently anchored by a US sales team led by Head of U.S. Sales Steve Green and a consulting CMO, Dr. Cyrus Raji — with channel distribution through INFINITT North America (access to 6,500+ PACS installations across 55 countries) and Rad Alliance. Notable clinical and research partners include UPMC, Medical College of Wisconsin, Washington University in St. Louis, Pacific Neuroscience Institute, and UCLA.
Brainreader is venture-backed (Insero, Investo Capital, Bevica Innovation, CBC Investment Group, and lead Series A investor Dahlgren Capital in May 2025 at $7.3M), ISO 13485:2016 certified, HIPAA-compliant, and operates from Aalborg, Denmark with a US headquarters in Tampa, Florida. A flagship commercial relationship is its exclusive partnership with Phenome Health on the Beyond the Human Genome Project, a ten-year, one-million-participant brain health trial.
Brainreader firmographics
Firmographics- Name
- Brainreader
- Legal name
- Brainreader A/S
- Website
- https://brainreader.net
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Brainreader is a Danish medtech company (founded 2011) that sells Neuroreader, an FDA-cleared AI software that quantifies 83 brain regions from routine MRI scans in under 10 minutes to support diagnosis and monitoring of neurodegenerative diseases for hospitals, imaging centers, and neurology/radiology practices.
- Ownership category
- akta.pro rank
Brainreader industry classification
Industry- Product category
- Medical Imaging Software
- NAICS
- Software Publishers (513210)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industry
- Medical Imaging AI (HDAAAEAH)
Keywords
Where Brainreader is headquartered
LocationHeadquarters
- HQ city
- Aalborg
- HQ country
- Denmark
- HQ region
- Europe
Offices2 records
Markets served
Brainreader business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- SaaS/Per-Use Brain Volumetric Analysis: Pay-per-use model where healthcare facilities pay per MRI scan analyzed. Simple pay-per-use pricing with no hardware or setup costs. Also available via subscription model tailored to healthcare organization preferences.
- Subscription Licensing: Annual or multi-year subscription licensing options for hospitals, imaging centers, and radiology departments.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | Pay-per-use model |
| Subscription | Annual | Subscription model for healthcare organizations |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Brainreader product offering
Product offeringCore offering
Brainreader develops Neuroreader, an FDA-cleared and CE-marked AI-powered medical software that automatically quantifies 83 brain regions from routine MRI scans in under 10 minutes. The platform provides objective volumetric measurements and statistical comparisons against an FDA-cleared normative database of healthy brain tissue, supporting detection and monitoring of neurodegenerative diseases such as Alzheimer's disease, traumatic brain injury, and frontotemporal dementia. The software integrates directly into existing PACS workflows via web upload or on-site mediation server, eliminating the need for additional hardware.
Product overview
Brainreader offers a single unified product platform centered on Neuroreader, an FDA-cleared and CE-marked AI-powered medical software for automated brain volumetric analysis. The platform provides quantitative MRI analysis by measuring 83 brain regions and comparing results against an FDA-cleared normative database, generating automated reports in under 10 minutes. Supporting resources include patient-facing educational materials, sample reports, and published case studies demonstrating clinical applications for Alzheimer's disease, traumatic brain injury, and other neurodegenerative conditions.
Differentiator
Problem solved
Functional benefit
Brands
- Neuroreader®: FDA-cleared and CE-marked AI-powered brain volumetric analysis software that quantifies 83 brain regions from routine MRI scans in less than 10 minutes for neurodegenerative disease detection.
Products and services
- Neuroreader FDA-cleared and CE-marked AI-powered brain volumetric analysis software that automatically quantifies 83 brain regions from routine MRI scans in under 10 minutes. Provides objective quantitative measurements, normative comparisons via an FDA-cleared healthy-brain database, and automated reports to support diagnosis and monitoring of neurodegenerative diseases including Alzheimer's, dementia, and traumatic brain injury. Targeted at hospitals, imaging centers, neurology and radiology practices, and academic research institutions.
- Neuroreader Sample Report Sample automated volumetric brain MRI report demonstrating Neuroreader's quantitative output including brain volume measurements, percentile rankings, Z-scores, and visual brain maps comparing patient scans against healthy normative databases. Provided on request to prospective customers.
- Neuroreader Patient Portal Patient-facing resource explaining how Neuroreader works alongside standard brain MRI to provide deeper insights into brain health, including information on conditions supported, the analysis process, and how patients can request the service from their physicians.
- Neuroreader Case Studies Published clinical case studies demonstrating Neuroreader's application in tracking Alzheimer's progression, frontotemporal dementia patterns, and longitudinal brain volume changes over time. Used to evidence clinical utility and outcomes for prospective customers.
Quantifiable outcome
- Reports generated in under 10 minutes, significantly faster than manual expert anatomical tracings which take 30+ minutes
- +3 more outcomes
Companies that use Brainreader
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
Brainreader technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature3 records
Brainreader partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship, core and supporting.
- Phenome HealthflagshipExclusive partnership to provide Neuroreader as sole volumetric brain analytics platform for landmark Beyond the Human Genome Project - a million-person brain health trial spanning ten years. Expected to enroll 100,000 participants yearly, resetting dementia treatment understanding worldwide.
- INFINITT North AmericacoreWide-ranging strategic partnership to expand FDA-cleared Neuroreader software through INFINITT's large North American customer base. INFINITT's enterprise imaging solutions serve over 6500 installations in 55 countries, providing significant distribution reach for Neuroreader's brain volumetric analysis.
- Aalborg UniversitysupportingThree-year R&D partnership supporting PhD research on AI and deep learning for neurodegenerative disease progression including Alzheimer's disease and Multiple Sclerosis. Daniel Ramsing Lund leads research combining established biomarkers with advanced deep learning techniques for brain MRI segmentation.
- Rad AlliancesupportingProfessional medical group providing international radiology imaging services with extensive experience in neuroimaging and volumetric analysis. Provides quality assurance program for Neuroreader cases to improve accuracy and optimization of images required to generate reports.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Brainreader competitors and assessment
Company assessmentDirect peers
- Cortechs.ai: Developer of NeuroQuant, an FDA-cleared MRI brain volumetric analysis tool that directly competes with Neuroreader in the same clinical workflow for measuring hippocampus and other brain regions to support neurodegenerative disease diagnosis.
- icometrix: Belgian-US company providing AI-based MRI brain quantification software (icolung, icoaspects, ibrain) for multiple sclerosis, dementia, and other neurological conditions, with direct overlap in volumetric brain analysis targeting hospitals and imaging centers.
Emerging players
- Combinostics: Finnish AI neuroimaging company offering brain MRI analysis tools (cDSI, cNeuro) for dementia and multiple sclerosis, addressing overlapping use cases in neurodegenerative disease quantification with a similar clinical customer base.
- Pixyl: French medtech developing AI-based brain MRI biomarkers for multiple sclerosis and other neurological disorders, competing in adjacent brain volumetric and lesion quantification workflows serving neuroradiology practices.
- Subtle Medical: AI medical imaging company focused on MRI image enhancement and quantification, addressing overlapping radiology customers and representing a potential adjacent or partial-overlap competitor for AI-based brain MRI analysis.
- Blackford Analysis: Provider of a curated marketplace and AI platform for medical imaging applications including brain analysis, targeting similar radiology and hospital customers through a channel/platform model.
Broad incumbents
- Aidoc: Major clinical AI imaging platform with broad FDA-cleared radiology AI modules that increasingly include neuro workflows; a broad incumbent whose enterprise footprint could overlap with Brainreader's target customer base.
- Viz.ai: Enterprise AI imaging platform with FDA-cleared neurovascular modules (stroke detection) sold to similar hospital and health system customers; represents a well-capitalized incumbent expanding into broader neurology AI workflows.
- Arterys: Cloud-native AI medical imaging platform with FDA-cleared modules across multiple modalities including neuro MRI, serving similar hospital and radiology enterprise customers with a broader portfolio than Brainreader's brain-focused offering.
Others
- Quanterix: Diagnostics and biomarker measurement company whose ultra-sensitive assays are used in neurodegenerative disease research and clinical trials; comparable in addressing the broader Alzheimer's and brain health biomarker market rather than directly competing on imaging AI.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Brainreader social profiles
Digital presenceBrainreader compliance and trust
Trust signalCompliance4 records
Brainreader financial estimates
Financial estimateRevenue estimate
Valuation estimate
Brainreader leadership team
Management profileNumber of profiles
Profiles7 records
Brainreader subsidiaries and ownership
Company hierarchySubsidiaries1 record
Brainreader funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Brainreader M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Brainreader
What does Brainreader do?
Brainreader develops Neuroreader, an FDA-cleared and CE-marked AI-powered medical software that automatically quantifies 83 brain regions from routine MRI scans in under 10 minutes. The platform provides objective volumetric measurements and statistical comparisons against an FDA-cleared normative database of healthy brain tissue, supporting detection and monitoring of neurodegenerative diseases such as Alzheimer's disease, traumatic brain injury, and frontotemporal dementia. The software integrates directly into existing PACS workflows via web upload or on-site mediation server, eliminating the need for additional hardware.
Is Brainreader a public or private company?
Brainreader is a private company. It is classified as venture growth investor backed and is currently operating.
When was Brainreader founded?
Brainreader was founded in 2011. It employs 1 to 10 people.
Where is Brainreader based?
Brainreader is headquartered in Aalborg, Denmark, in the Europe region.
How does Brainreader make money?
Two revenue lines are on record. SaaS/Per-Use Brain Volumetric Analysis are the primary driver. The others are subscription Licensing.
Who are Brainreader's main competitors?
Direct peers on record are Cortechs.ai and icometrix. Emerging players are Combinostics, Pixyl, Subtle Medical and Blackford Analysis. Broad incumbents are Aidoc, Viz.ai and Arterys. Quanterix is listed as an others.
Does Brainreader have an API?
No public API is recorded for Brainreader.
What industry is Brainreader in?
Brainreader's product category is Medical Imaging Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 513210 and its SIC code is 7372.